Intelligence · Clinical pipeline
Oncology R&D Pipeline
Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
Quick answer
Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
Top sponsors
- First People's Hospital 474 programs
- Chinese Academy of 400 programs
- United Therapeutics Europe 219 programs
- George Institute for 172 programs
- Takeda 163 programs
- HOFFMANN-LA ROCHE 144 programs
- AstraZeneca 143 programs
- MSD Merck Sharp 131 programs
- Regeneron UK 128 programs
- Anaxis Pharma 125 programs
- Telethon Foundation 113 programs
- Novartis India 110 programs
Pipeline programs
-
Toripalimab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Triple-Negative Breast Cancer (TNBC)
1 trial -
Toripalimab
The First People's Hospital of Lianyungang
Urinary Bladder Neoplasms
1 trial -
Toripalimab
The First People's Hospital of Lianyungang
Small Cell Lung Cancer Limited Stage
1 trial -
Toripalimab
The First People's Hospital of Lianyungang
Upper Tract Urothelial Carcinoma
1 trial -
Toripalimab
The First People's Hospital of Lianyungang
Pancreatic Carcinoma
1 trial -
Toripalimab
Yongchang Zhang
Advanced Non Small Cell Lung Cancer
1 trial -
Toripalimab
The First People's Hospital of Lianyungang
Nasopharyngeal Carcinoma
1 trial -
Toripalimab
The First People's Hospital of Lianyungang
Locally Advanced Colon Cancer
1 trial -
Toripalimab
The First People's Hospital of Lianyungang
Breast Cancer
1 trial -
Toripalimab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Tracheal Squamous Cell Carcinoma
1 trial -
Toripalimab + Chemotherapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Thymic Epithelial Tumor
1 trial -
Toripalimab + Chemotherapy
Coherus Oncology
Head and Neck Cancer
1 trial -
Toripalimab+Nedaplatin+Albumin Paclitaxel
The First People's Hospital of Lianyungang
Locally Advanced Esophageal Squamous Cell Carcinoma
1 trial -
Toripalimab-tpzi
Coherus Oncology
Squamous Cell Carcinoma
1 trial -
Total Neoadjuvant Treatment
The First People's Hospital of Lianyungang
Biliary Tract Neoplasms
1 trial -
Tovorafenib, Tovorafenib
Lacuna Pharma Pty Ltd
RAF-Altered, Recurrent or Progressive Low-Grade Glioma and Advanced Solid Tumors in pediatric patients
1 trial -
Trametinib (GSK1120212)
ADIAL PHARMACEUTICALS, INC.
Melanoma
1 trial -
Transarterial chemoembolization
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Unresectable Colorectal Cancer
1 trial -
Trastuzumab
United Therapeutics Europe Ltd
Metastatic Colorectal Adenocarcinoma
1 trial -
Trastuzumab
KAZIA THERAPEUTICS LTD
Breast Cancer
1 trial -
Trastuzumab
United Therapeutics Europe Ltd
Metastatic Colon Adenocarcinoma
1 trial -
Trastuzumab
PUMA BIOTECHNOLOGY, INC.
Metastatic Colorectal Cancer
1 trial -
Trastuzumab deruxtecan
AstraZeneca
Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast
1 trial -
Trastuzumab in Combination with TS-ONE and cisplatin
Hospital Authority, Hong Kong
Gastric Cancer
1 trial -
Trilaciclib
The First People's Hospital of Lianyungang
Osteosarcoma
1 trial -
Trilaciclib
The First People's Hospital of Lianyungang
Advanced Squamous Non-Small-Cell Lung Cancer
1 trial -
Trilaciclib and Sacituzumab Tirumotecan
The First People's Hospital of Lianyungang
NSCLC (Advanced Non-small Cell Lung Cancer)
1 trial -
Trodelvy 200 mg powder for concentrate for solution for infusion
Gilead Sciences Pty Limited
Metastatic Solid Tumors
1 trial -
Tumor infiltrating lymphocytes (TIL) LN-145
Iovance Biotherapeutics B.V.
Metastatic Triple Negative Breast Cancer
1 trial -
Tunlametinib+PD-1 mAb
BEONE MEDICINES AUS PTY LTD
Gastric Adenocarcinoma
1 trial -
Tuspetinib
Aptose Biosciences
Leukemia, Myeloid, Acute
1 trial -
U1111-1305-0044
The George Institute
Early triple-negative breast cancer (TNBC)
1 trial -
UC-0107/1810
Ningbo Cancer Hospital
BRAF(V600) mutation-positive melanoma with brain metastasis (MBM)
1 trial -
UC-0110/1608
Ningbo Cancer Hospital
RAS and B-RAF wild-type metastatic colorectal cancer. RAS and B-RAF mutation will be determined using circulating cell-free DNA (ccfDNA) by IntPlex method
1 trial -
UC-0110/1719
Ningbo Cancer Hospital
Localised unresectable adenocarcinoma or squamous cell carcinoma of the oesophagus without any prior chemotherapy, surgery, or radiotherapy
1 trial -
UC-0140/1711_UCBG3
Ningbo Cancer Hospital
Triple-negative androgen receptor positive (molecular apocrine-like HER2-negative subtype) locally recurrent (unresectable) or metastatic breast cancer.
1 trial -
UC-0140/1812
Ningbo Cancer Hospital
ER-positive and HER2-negative metastatic or locally advanced breast cancer with either a germline or somatic BRCA mutation, or a deleterious alteration of other genes involved in homologous recombination repair (HRR) or in MSI status.
1 trial -
UC-0150/1704
Ningbo Cancer Hospital
Patients ≤50 years old with high-risk osteosarcoma (defined as metastatic osteosarcoma at diagnosis or localised osteosarcoma with poor histological response) after pre-operative chemotherapy and surgery of the primary tumour and lung metastases (if applicable).
1 trial -
UC-BCG-2011
Ningbo Cancer Hospital
HER2+ metastatic breast cancer with isolated brain progression
1 trial -
UC-BCG-2103
Ningbo Cancer Hospital
Post-menopausal women with localized luminal A breast cancer and considered at low risk of metastatic relapse
1 trial -
UC-BCG-2211, CAPPA
Ningbo Cancer Hospital
Triple Negative Breast Cancer with residual disease after neoadjuvant chemo-immunotherapy.
1 trial -
UC-BCG-2213
The George Institute
Triple negative breast cancer
1 trial -
UC-BCG-2312
Ningbo Cancer Hospital
Patients with HER2-positive locally advanced inoperable or metastatic breast cancer with disease controlled after 2 years of maintenance treatment with anti-HER2 targeted therapy
1 trial -
UC-BCG-2513
Ningbo Cancer Hospital
Postmenopausal patients with small (pT1a-b pN0) hormone receptor positive (HR⁺) and HER2 negative (HER2⁻) early breast cancer with a Luminal A phenotype and at low risk of recurrence.
1 trial -
UC-GIG-2023
Ningbo Cancer Hospital
Patients with HER 2 negative locally advanced, recurrent or metastatic gastric, oesophagus or gastroesophageal junction adenocarcinoma
1 trial -
UC-GIG-2308
Ningbo Cancer Hospital
Patients with pMMR/MSS metastatic adenocarcinoma of the colon or rectum or gastroesophageal cancer (lower esophagus, gastroesophageal junction and gastric) and with known dihydropyrimidine dehydrogenase (DPD) deficiency defined as plasma uracil concentration ≥16 ng/ml, who undergo first-line treatment
1 trial -
UC-GIG-2311
Ningbo Cancer Hospital
Fluoropyrimidine (FP)-naive patients with gastrointestinal (GI) cancer and available pre-treatment uracilemia ([U]) starting chemotherapy combining FP (5FU or capecitabine) and oxaliplatin for any indication
1 trial -
UC-GIG-2404
Ningbo Cancer Hospital
Advanced biliary tract cancer (BTC)
1 trial
Frequently asked questions
How many oncology pipeline programs are tracked?
5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.
Where does pipeline data come from?
ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.